🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsRetatrutide & Triple AgonistsGCG receptor signaling deep dive — anyone have experience?

GCG receptor signaling deep dive — anyone have experience?

zoe_NC Sun, Jan 4, 2026 at 9:44 AM 24 replies 1,337 viewsPage 1 of 5
zoe_NC
Member
278
1,234
Nov 2024
Charlotte, NC
Jan 4, 2026 at 9:44 AM#1

Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.

The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.

The bit I cannot resolve on my own is which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working. I would rather have one careful answer than five confident ones.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
13 8Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 10 others
Reply Quote Save Share Report
amsterdam_pete
Senior Member
1,567
6,789
Feb 2024
Netherlands
Jan 4, 2026 at 10:45 AM#2
zoe_NC said:
The mechanism is more central than most summaries suggest.

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest trajectory ever seen for an anti-obesity agent[1].

Amylin receptor agonism enhances satiety signaling through the area postrema and reduces glucagon secretion. Combined with GLP-1R agonism, this dual mechanism may produce even greater efficacy than current agents.

Early-stage data — interpret with caution. But the trajectory is extraordinary.

References:
[1] Novo Nordisk investor presentation, September 2023.
12 7ZaraB_AL, JakeSmashed95, NauseaFreeNow and 9 others
Reply Quote Save Share Report
PharmD_Rodriguez
Senior Member
3,456
14,567
Jan 2024
Miami, FL
Jan 4, 2026 at 11:46 AM#3
zoe_NC said:
The mechanism is more central than most summaries suggest.

This is where I part company with the consensus forming above. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

11 6robert_kc, dan_philly, MeganSA_TX and 8 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Jan 4, 2026 at 12:47 PM#4
PharmD_Rodriguez said:
The pharmacokinetics explain nearly every practical question asked here.

Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36). Three key modifications enable its pharmacokinetic profile:

  1. Aib8 substitution: DPP-4 resistance (prevents enzymatic degradation)
  2. Arg34 substitution: improved chemical stability
  3. C18 fatty diacid at Lys26: albumin binding → long half-life

These three modifications transform a peptide with a 2-minute half-life (native GLP-1) into one with a 168-hour half-life (semaglutide). A masterclass in peptide engineering.

Last edited: Jan 4, 2026 at 1:47 PM
10 5DebRD_ATL, KristenIndy, MarkLI_maint and 7 others
Reply Quote Save Share Report
hans_munich
Member
534
2,345
Jul 2024
Munich, DE
Jan 4, 2026 at 6:35 PM#5
amsterdam_pete said:
Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

Same pattern here, and in the same order. Posting only so the count is not one.

Last edited: Jan 5, 2026 at 12:35 AM
9 4emma_london, tammy_FL, Dr.LipidDallas and 6 others
Reply Quote Save Share Report
1235

Similar Threads

TRIUMPH-3 topline results — 24.2% body weight loss at 48 weeks10 replies
Retatrutide mechanism: GLP-1/GIP/glucagon triple agonism explained5 replies
Retatrutide Phase 2 dose-response analysis — optimal dose range10 replies
Glucagon receptor agonism and hepatic lipid oxidation — MASH implications13 replies
Retatrutide vs tirzepatide — dual vs triple agonist comparison22 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register